Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

INTRODUCTION: Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo Re, Marianna, Capobianco, Marco, Ragonese, Paolo, Realmuto, Sabrina, Malucchi, Simona, Berchialla, Paola, Salemi, Giuseppe, Bertolotto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685862/
https://www.ncbi.nlm.nih.gov/pubmed/26647006
http://dx.doi.org/10.1007/s40120-015-0038-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685862/
https://www.ncbi.nlm.nih.gov/pubmed/26647006
http://dx.doi.org/10.1007/s40120-015-0038-9

Ejemplares similares